Leonard Post, PhD
CSO Vivace Therapeutics

Dr. Leonard Post is Vivace’s chief scientific officer and a member of the board of directors, as well as CSO for Vivace's sister company, Virtuoso Therapeutics. He brings more than three decades of pharmaceutical experience spanning companies of all sizes.

Before joining Vivace in 2016, Len served as CSO of BioMarin, a publicly held biopharmaceutical firm with a focus on rare diseases. He joined BioMarin in 2010, when the company acquired LEAD Therapeutics, and was responsible for the inception as well as subsequent development of talazoparib. Len held various positions at BioMarin from 2010–2016, during which time he oversaw the initiation of BioMarin's first gene therapy project for hemophilia A. Positions prior to LEAD included senior vice president of research and development for Onyx Pharmacueticals and vice president of discovery research for Parke-Davis Pharmaceuticals.

A virologist by training, Len did early work on the engineering of the herpes simplex virus genome as a postdoctoral fellow. He holds a doctorate in biochemistry from the University of Wisconsin, and a B.S. in chemistry from the University of Michigan.